The DOI matches its Crossref record; 195 of the 195 references it cites were found in a registry or an index.
Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests
Open accessAbstract
Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and is often associated with aspects of metabolic syndrome. Despite its prevalence and the importance of early diagnosis, there is a lack of robustly validated biomarkers for diagnosis, prognosis and monitoring of disease progression in response to a given treatment. In this Review, we provide an overview of the contribution of metabolomics and lipidomics in clinical studies to identify biomarkers associated with NAFLD and nonalcoholic steatohepatitis (NASH). In addition, we highlight the key metabolic pathways in NAFLD and NASH that have been identified by metabolomics and lipidomics approaches and could potentially be used as biomarkers for non-invasive diagnostic tests. Overall, the studies demonstrated alterations in amino acid metabolism and several aspects of lipid metabolism including circulating fatty acids, triglycerides, phospholipids and bile acids. Although we report several studies that identified potential biomarkers, few have been validated.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Despite some limitations regarding sample size, different clinical characteristics of the patients, and the methods of lipidomic profile detection, most of the studies were concordant in showing that individuals with MASLD have higher hepatic accumulation of TAGs, DAGs, ceramides, and dihydroceramides, and in general of lipids rich in SFAs.95”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [95]
In the citing paper
“Individuals with MASH had significantly lower long-chain polyunsaturated fatty acids (PUFAs) and some species of phosphatidylethanolamine (PE), and they had significantly higher lysophosphatidylethanolamine vs. those with isolated steatosis.”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [95]
In the citing paper
“In contrast, some lipid species like PCs and LPCs were significantly reduced compared to controls without MASLD.”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [95]
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
Self-citationEASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Newgard, C. B., An, J., Bain, J. R., Muehlbauer, M. J., Stevens, R. D., Lien, L. F., Haqq, A. M., Shah, S. H., Arlotto, M., Slentz, C. A., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.02.002 · Cited by 3,165
Metabolite profiles and the risk of developing diabetes
Wang, T. J., Larson, M. G., Vasan, R. S., Cheng, S., Rhee, E. P., McCabe, E., Lewis, G. D., Fox, C. S., Jacques, P. F., Fernandez, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2307 · Cited by 3,143
Bile salt biotransformations by human intestinal bacteria
Ridlon, J. M., Kang, D.-J., & Hylemon, P. B. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r500013-jlr200 · Cited by 2,829
Human Fatty Liver Disease: Old Questions and New Insights
Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089
(2012) · Hepatogastroenterology · doi:10.5754/hge12183 · Cited by 1,625
Research works printed but not linked: 1
- Wolfe, R. R. & Chinkes, D. L. Isotope Tracers in Metabolic Research: Principles and Practice of Kinetic Analysis (Wiley, 2004).
Cited by
Cusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.010 · Cited by 1,021
Small molecule metabolites: discovery of biomarkers and therapeutic targets
Qiu, S., Cai, Y., Yao, H., Lin, C., Xie, Y., Tang, S., & Zhang, A. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01399-3 · Cited by 884
The multifaceted role of ferroptosis in liver disease
Chen, J., Li, X., Ge, C., Min, J., & Wang, F. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-022-00941-0 · Cited by 665
Neeland, I. J., Lim, S., Tchernof, A., Gastaldelli, A., Rangaswami, J., Ndumele, C. E., Powell-Wiley, T. M., & Després, J.-P. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00563-5 · Cited by 463
Self-citationGut symbionts alleviate MASH through a secondary bile acid biosynthetic pathway
Nie, Q., Luo, X., Wang, K., Ding, Y., Jia, S., Zhao, Q., Li, M., Zhang, J., Zhuo, Y., Lin, J., et al. (2024) · Cell · doi:10.1016/j.cell.2024.03.034 · Cited by 326
Metadata
- Authors
- Masoodi, M., Gastaldelli, A., Hyötyläinen, T., Arretxe, E., Alonso, C., Gaggini, M., Brosnan, J., Anstee, Q. M., Millet, O., Ortiz, P., Mato, J. M., Dufour, J.-F., & Orešič, M.
- Affiliations
- University Hospital of Bern (CH)
- Istituto di Fisiologia Clinica (IT)
- Örebro University (SE)
- Euskadiko Parke Teknologikoa (ES)
- Pfizer (United States) (US)
- Newcastle University (GB)
- Åbo Akademi University (FI)
- Corresponding author
- Masoodi, Mojgan
- Orešič, Matej
- ORCID
- Venue
- Nature Reviews Gastroenterology & Hepatology
- Published
- 2021-09-10
- Volume
- 18
- Issue
- 12
- Pages
- 835-856
- ISSN
- 1759-5045 (ISSN-L)
- 1759-5053
- OpenAlex
- W3197814387
- Cited by
- 451
- References
- 195
- Citations by year
- 2026: 69 · 2025: 104 · 2024: 109 · 2023: 95 · 2022: 70 · 2021: 4
- FWCI
- 11.13
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Gastroenterology & Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Bern Open Repository and Information System (University of Bern) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, metabolomics, lipidomics, biomarkers, non-invasive diagnosis, amino acid metabolism, lipid metabolism, circulating fatty acids, triglycerides, phospholipids, bile acids, metabolic pathways, metabolic syndrome
- MeSH terms
- Lipidomics, Amino Acids, Bile Acids and Salts, Glutathione, Humans, Insulin Resistance, Prognosis, Biomarkers, Disease Progression, Glutamic Acid, Lipid Metabolism, Metabolomics, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. https://app.cochat.ai/papers/10.1038/s41575-021-00502-9
- The paper
- Masoodi, M., Gastaldelli, A., Hyötyläinen, T., Arretxe, E., Alonso, C., Gaggini, M., Brosnan, J., Anstee, Q. M., Millet, O., Ortiz, P., Mato, J. M., Dufour, J.-F., & Orešič, M. (2021). Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nature Reviews Gastroenterology & Hepatology. https://doi.org/10.1038/s41575-021-00502-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.